Analyst consensus rating
Relmada Therapeutics Analyst Rating: Strong Buy
RLMD is rated Strong Buy by 6 analysts with a $12.67 target. As of 2026-08-22.
Direct answer
Relmada Therapeutics's consensus rating is Strong Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $12.67.
Forecast evidence checked August 22, 2026.
Get free Relmada Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.63
- Average price target
- $12.67
- High price target
- $19.00
- Low price target
- $9.00
- Low target gap
- +94.4%
- Target upside
- +173.6%
- High target gap
- +310.4%
- Target range width
- 216%
- Consensus rating
- Strong Buy
- Analysts
- 6
- Evidence date
- August 22, 2026
- Valid through
- August 29, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Relmada Therapeutics?
Relmada Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $12.67.
How far are Relmada Therapeutics's low and high targets from the recorded price?
The low target implies +94.4%, while the high target implies +310.4%.
How many analysts are included in Relmada Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is Relmada Therapeutics's target upside or downside calculated?
The average target of $12.67 is divided by the recorded price of $4.63, then one is subtracted to produce +173.6%. This does not guarantee a future return.
When was Relmada Therapeutics's analyst forecast verified?
The data was verified on 2026-08-22. The dataset is valid through 2026-08-29.